IBM Watson, Pfizer join forces on cancer drug discovery

IBM Watson and Pfizer teamed up in a new arrangement that will bring supercomputing capabilities to cancer drug discovery. Pfizer, in fact, will employ Watson for Drug Discovery’s machine learning, natural language processing and other cognitive reasoning technologies to identify new drugs, combination therapies and patient selection strategies in immuno-oncology. Immuno-oncology is an approach to cancer treatment that uses the body’s immune system to help fight cancer, the companies said. Oncology researchers at Pfizer will use Watson to analyze massive volumes of disparate data, including licensed and publicly available data as well as Pfizer’s proprietary data. Employing Watson, Pfizer researchers will analyze and test hypotheses to generate evidence-based insights. According to Pfizer, many researchers believe that the future of immuno-oncology lies in combinations tailored to unique tumor characteristics, which could…

Link to Full Article: IBM Watson, Pfizer join forces on cancer drug discovery

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!